.svg){kind=small}
Sep-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Avexia has demonstrated a robust performance in the Illinois market, particularly in the Topical category, where it maintained its top position from June to September 2025. However, the Capsules category revealed a steady hold at the second position, despite a notable decline in sales by September. Interestingly, while Avexia started strong in the Concentrates category, it experienced a downward trajectory, slipping from 12th to 22nd position over the same period. This fluctuation in rankings could indicate shifting consumer preferences or increased competition within the state.
In Maryland, Avexia also performed well in the Capsules category, consistently holding the second rank. However, the Topical category saw a slight dip from first to second place in August, though it continued to perform strongly overall. The brand's performance in the Concentrates category was less stable, with rankings fluctuating between 19th and 24th place. Meanwhile, in New Jersey, Avexia maintained its leading position in the Topical category for most of the period, despite a drop to second place in September. The absence of rankings in the Capsules and Tincture & Sublingual categories after June suggests potential challenges in maintaining market presence in these segments. In Ohio, Avexia's performance in the Concentrates category was limited, entering the top 30 only in July, while maintaining a consistent rank in the Tincture & Sublingual category.
Competitive Landscape
In the Illinois Topical cannabis market, Avexia has consistently maintained its leading position, ranking first from June through September 2025. This dominance is underscored by its sales growth, which saw a steady increase from June to September, reflecting a strong consumer preference and effective market strategies. In contrast, Doctor Solomon's, while holding the second position throughout the same period, experienced a notable decline in sales by September, which could indicate a potential vulnerability or shift in consumer loyalty. Meanwhile, Alchemy (Ieso) entered the top rankings in August and maintained its fourth position into September, suggesting a growing presence in the market. These dynamics highlight Avexia's robust market leadership amidst fluctuating performances from its competitors, suggesting that Avexia's strategies are effectively capturing and retaining consumer interest in the Illinois Topical category.
Notable Products
In September 2025, the CBD/THC 1:1 Harmony Pain Relief Balm maintained its top position as the leading product from Avexia, continuing its streak as the number one ranked product since June 2025, with sales figures reaching 8,869 units. The CBD/THC 4:1 Relief Tablets held steady in the second position, although its sales have seen a gradual decline over the months. The CBN/CBD/THC 1:1:1 Comfort Tablets also retained its third-place ranking, but like the Relief Tablets, it experienced a drop in sales figures. The CBD/THC 1:1 Harmony Micro-Dosed Tablets and CBG/THC 1:1 Ascend Tablets similarly maintained their fourth and fifth positions, respectively, despite a consistent decrease in sales each month. Overall, the rankings have remained unchanged from previous months, indicating a stable preference pattern among consumers for these Avexia products.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
